Some of these potential antibody targets might be candidates for chimeric antigen receptor-modified T-cell immunotherapy; some clinical and preclinical trials evaluated HER2- or GD2-specific chimeric antigen receptor-modified T cell immunotherapy for sarcoma (dominantly osteosarcoma), and the results demonstrated the therapy’s tolerance and safety; the objective response rate has not been reported at this time [59,60]. This evidence concerns the gene ERBB2 and osteosarcoma.